Figure 1From: Emerging role of anti-tumor necrosis factor therapy in rheumatic diseasesPsoriasis plaques on patient skin. Depicted is a representative set of patient plaques (a) before and (b) 10 weeks after infliximab treatment. Note the characteristic sharply circumscribed erythematous psoriasis plaque covered by silvery scales prior to infliximab therapy.Back to article page